Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera
Vanda Pharmaceuticals (Nasdaq: VNDA) announced that its novel drug candidate VGT-1849B has received FDA Orphan Drug Designation for the treatment of polycythemia vera (PV), a rare blood disorder affecting 44-57 per 100,000 people in the US.
VGT-1849B is a selective peptide nucleic acid-based JAK2 inhibitor that specifically targets JAK2 mRNA, distinguishing itself from existing treatments like Jakafi®, Inrebic®, Ojjaara®, and Vonjo® which are not JAK2-selective. The drug's unique OPNA backbone chemistry enhances cell permeability and RNA affinity, potentially offering improved safety and less frequent dosing compared to current treatments.
Vanda Pharmaceuticals (Nasdaq: VNDA) ha annunciato che il suo nuovo candidato farmaco VGT-1849B ha ottenuto la designazione di Farmaco Orfano dalla FDA per il trattamento della policitemia vera (PV), una rara malattia del sangue che colpisce 44-57 persone ogni 100.000 negli Stati Uniti.
VGT-1849B è un inibitore selettivo di JAK2 basato su peptide nucleico che mira specificamente all'mRNA di JAK2, distinguendosi dai trattamenti esistenti come Jakafi®, Inrebic®, Ojjaara® e Vonjo®, che non sono selettivi per JAK2. La chimica unica del suo backbone OPNA migliora la permeabilità cellulare e l'affinità per l'RNA, offrendo potenzialmente una maggiore sicurezza e dosaggi meno frequenti rispetto alle terapie attuali.
Vanda Pharmaceuticals (Nasdaq: VNDA) anunció que su nuevo candidato farmacológico VGT-1849B ha recibido la Designación de Medicamento Huérfano por la FDA para el tratamiento de la policitemia vera (PV), un raro trastorno sanguíneo que afecta a 44-57 personas por cada 100.000 en EE. UU.
VGT-1849B es un inhibidor selectivo de JAK2 basado en péptido nucleico que dirige específicamente el ARNm de JAK2, diferenciándose de tratamientos existentes como Jakafi®, Inrebic®, Ojjaara® y Vonjo®, que no son selectivos para JAK2. La química única de su esqueleto OPNA mejora la permeabilidad celular y la afinidad por el ARN, ofreciendo potencialmente una mayor seguridad y una dosificación menos frecuente en comparación con las terapias actuales.
Vanda Pharmaceuticals (Nasdaq: VNDA)� 신약 후보물질 VGT-1849B갶 진성 적혈구증갶�(PV) 치료제로 FDA 희귀의약� 지�(Orphan Drug Designation)� 받았다고 발표했습니다. PV� 미국에서 인구 10� 명당 44~57명이 걸리� 희귀 혈액 질환입니�.
VGT-1849B� 펩타이드 뉴클레오� 기반� 선택� JAK2 억제제로, JAK2 mRNA� 직접 표적화하� Jakafi®, Inrebic®, Ojjaara® � Vonjo®와 달리 JAK2 선택성이 있습니다. 고유� OPNA 골격 화학은 세포 투과성과 RNA 친화성을 향상시켜, 현재 치료법에 비해 안전성이 개선되고 투약 간격� 길어� 갶능성� 제공합니�.
Vanda Pharmaceuticals (Nasdaq: VNDA) a annoncé que son candidat-médicament VGT-1849B a reçu la désignation de médicament orphelin par la FDA pour le traitement de la polycythémie vraie (PV), une maladie sanguine rare touchant 44 à 57 personnes sur 100 000 aux États-Unis.
VGT-1849B est un inhibiteur sélectif de JAK2 à base d'acide peptidique nucléique ciblant spécifiquement l'ARNm de JAK2, ce qui le distingue des traitements existants tels que Jakafi®, Inrebic®, Ojjaara® et Vonjo®, qui ne sont pas sélectifs pour JAK2. La chimie unique de son squelette OPNA améliore la perméabilité cellulaire et l'affinité pour l'ARN, offrant potentiellement une meilleure sécurité et une posologie moins fréquente par rapport aux traitements actuels.
Vanda Pharmaceuticals (Nasdaq: VNDA) gab bekannt, dass sein neuer Arzneimittelkandidat VGT-1849B von der FDA die Zulassung als Orphan Drug für die Behandlung der Polycythaemia vera (PV) erhalten hat, einer seltenen Bluterkrankung, die in den USA 44�57 von 100.000 Personen betrifft.
VGT-1849B ist ein selektiver, peptidnukleinsäure-basierter JAK2-Inhibitor, der gezielt JAK2-mRNA anspricht und sich damit von bestehenden Behandlungen wie Jakafi®, Inrebic®, Ojjaara® und Vonjo® unterscheidet, die nicht JAK2-selektiv sind. Die einzigartige OPNA-Backbone-Chemie verbessert die Zellpermeabilität und RNA-Affinität und könnte potenziell eine verbesserte Sicherheit und weniger häufige Dosierung gegenüber aktuellen Therapien bieten.
- FDA Orphan Drug Designation granted, providing development benefits
- Novel selective JAK2 inhibitor with potential improved safety profile compared to existing treatments
- Targets large addressable market with PV affecting 44-57 per 100,000 people in the US
- Potential for more convenient dosing schedule if approved
- Drug is still in early development stages with no efficacy data presented
- Will face competition from established JAK inhibitors in the market
Insights
FDA Orphan Drug Designation for Vanda's selective JAK2 inhibitor could offer competitive advantages in polycythemia vera treatment if approved.
Vanda Pharmaceuticals has achieved a significant regulatory milestone with the FDA granting Orphan Drug Designation for VGT-1849B, their novel JAK2 inhibitor for polycythemia vera (PV). This designation provides important development incentives for addressing this rare blood disorder affecting approximately 44-57 per 100,000 Americans.
The technology behind VGT-1849B represents a potentially important advancement in targeting precision. Unlike existing JAK inhibitors (Jakafi®, Inrebic®, Ojjaara®, and Vonjo®), VGT-1849B employs an antisense oligonucleotide approach with OliPass Peptide Nucleic Acid (OPNA) technology to specifically target JAK2 mRNA. This selectivity could be clinically meaningful since over 95
The selective nature of VGT-1849B potentially addresses a significant limitation of current therapies. Existing JAK inhibitors lack selectivity for JAK2, leading to off-target effects on JAK1, JAK3, TYK2, and other kinases that can cause immunosuppression and other toxicities. By precisely targeting JAK2 mRNA, VGT-1849B could theoretically maintain efficacy while reducing adverse effects seen with pan-JAK inhibitors, particularly infection risks.
Additionally, the press release mentions "convenient infrequent dosing," suggesting potential administration advantages that could improve patient adherence compared to daily oral medications. While the candidate remains in early development stages, this regulatory milestone enhances Vanda's position in developing treatments for orphan hematological conditions.
PV is a chronic myeloproliferative disorder characterized by aberrant hematopoiesis of myeloid lineage with exuberant red cell production and increased release of pro-inflammatory cytokines. More than
VGT-1849B is an antisense oligonucleotide (ASO) that utilizes a novel backbone chemistry, OliPass Peptide Nucleic Acid (OPNA), that has been derived from peptide nucleic acid (PNA) by rationally introducing cationic lipid moieties onto nucleobases. By covalently attaching cationic lipid groups onto PNA, cell permeability and affinity for RNA are markedly improved.
By selectively targeting JAK2 mRNA, VGT-1849B reduces downstream signaling and JAK2V617F-driven autonomous cell proliferation. VGT-1849B targets JAK2 with high precision and effectively reduces JAK2 protein production, without any off-target kinase effects. Inhibiting JAK2 acts to suppress hematopoiesis, consequently reducing red blood cell, neutrophil, platelet, and lymphocyte production. The ability of VGT-1849B to reduce JAK2 protein may alleviate the disease burden that patients with PV face with a favorable safety profile, resulting in a higher quality of life for patients.
JAK2 inhibitors have been shown to be efficacious in treating various JAK-dependent hematologic malignancies, including the treatment of PV. While there are several JAK inhibitors available such as Jakafi®, Inrebic®, Ojjaara®, and Vonjo®, none are solely selective to JAK2. Due to the highly conserved structure of the catalytic sites of protein kinases, JAK2 inhibitors may bind to off-target kinases, leading to increased toxicity and a worse overall safety profile. The adverse side effects that may occur from JAK inhibition emphasize the importance of selectively targeting JAK2 while avoiding inhibition of other JAK family members. By specifically targeting JAK2, we aim to reduce the risk of infection and toxic effects that are seen with inhibitors that also block JAK1, JAK3, TYK2, or other kinases outside of the JAK family.
If approved, VGT-1849B could offer targeted efficacy with an improved safety profile and convenient infrequent dosing.
Orphan Drug Designation is granted by the FDA to investigational therapies addressing rare medical conditions and provides benefits to drug developers.
References
- P. Gou, W. Zhang, and S. Giraudier, "Insights into the Potential Mechanisms of JAK2V617F Somatic Mutation Contributing Distinct Phenotypes in Myeloproliferative Neoplasms," Myeloproliferative Neoplasms. Int. J. Mol. Sci, vol. 2022, p. 1013, 2022, doi: 10.3390/ijms.
- Grunwald, M. R.; Stein, B. L.; Boccia, R. V.; Oh, S. T.; Paranagama, D.; Parasuraman, S.; Colucci, P.; Mesa, R. Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in
the United States . Clin Lymphoma Myeloma Leuk 2018, 18 (12), 788-795.e2. .
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit and follow us on X @vandapharma.
About VGT-1849B
VGT-1849B is an antisense oligonucleotide (ASO) that utilizes a novel backbone chemistry, OliPass Peptide Nucleic Acid (OPNA) peptide nucleic acid, and selectively targets JAK2 mRNA, reducing aberrant levels of JAK2 that may cause hematologic malignancies. OPNA was derived from PNA through rational chemical modifications to enhance cell permeability and RNA affinity. For therapeutic intervention, OPNA potently binds to target pre-mRNA, induces exon skipping, and yields an mRNA splice variant. Unlike other types of RNA therapeutics, OPNA does not require formulation aid for in vivo therapeutic activity. OPNA oligonucleotide-based therapeutics have broad applicability in addressing a number of disorders caused by genetic variants.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Various statements in this press release, including, but not limited to statements regarding the estimated prevalence of PV in
All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this press release is provided only as of the date of this press release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
[email protected]
Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
[email protected]
View original content to download multimedia:
SOURCE Vanda Pharmaceuticals Inc.